Effect of spironolactone use in pulmonary arterial hypertension – analysis from pivotal trial databases

Keyphrases

• Pulmonary Arterial Hypertension 100%
• Pivotal Trial 100%
• Spironolactone 100%
• Hypertension Patients 27%
• Patient Demographics 18%
• 6-minute Walk Distance (6MWD) 18%
• Clinical Worsening 18%
• World Health Organization Functional Class 18%
• Adverse Effects 9%
• Pulmonary Vascular 9%
• Improved Outcomes 9%
• Cardiac Index 9%
• Diuretics 9%
• Disease Severity 9%
• Patient Outcomes 9%
• All-cause Mortality 9%
• Disease Process 9%
• Severe Heart Failure 9%
• Large Cohort 9%
• Receptor Function 9%
• Vascular Remodeling 9%
• Dyspnea Score 9%
• Vascular Pathology 9%
• Arterial Pressure 9%
• Right Heart Failure 9%
• Hypertension Disease 9%
• Propensity Analysis 9%
• Pulmonary Microvascular Endothelial Cells (PMVECs) 9%
• Current Analysis 9%
• Hyperaldosteronism 9%
• Endothelin B Receptor 9%
• Treprostinil 9%
• Cardiopulmonary Hemodynamics 9%
• Left Heart Disease 9%

Biochemistry, Genetics and Molecular Biology

• Endothelin Receptor Type B 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Hyperaldosteronism 9%